Flagship Pioneering unveiled Expedition Medicines with an initial $50 million investment to build an AI‑driven drug discovery company focused on cancer and immune diseases. The new startup already disclosed a partnership with Pfizer to discover and optimize small molecules using Expedition’s generative chemistry and AI platform. Flagship’s repeat launches of AI biotechnology firms signal continued belief that large‑scale computational approaches will compress target identification and candidate generation. The team positions Expedition to move quickly from in silico discovery to partnered preclinical optimization. Investors and pharma partners are watching whether Expedition can produce clinical‑grade candidates faster than traditional discovery models; Pfizer’s early engagement provides a commercial validation vector.